Bristol-Myers Squibb Company Ce
CELG-RI · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $68 | $51 | $102 | $99 |
| - Cash | $15,726 | $12,613 | $10,875 | $10,346 |
| + Debt | $51,041 | $50,929 | $51,239 | $51,200 |
| Enterprise Value | $35,383 | $38,367 | $40,466 | $40,953 |
| Revenue | $12,222 | $12,269 | $11,201 | $12,342 |
| % Growth | -0.4% | 9.5% | -9.2% | – |
| Gross Profit | $8,066 | $8,070 | $7,340 | $7,424 |
| % Margin | 66% | 65.8% | 65.5% | 60.2% |
| EBITDA | $4,620 | $3,287 | $4,492 | $2,540 |
| % Margin | 37.8% | 26.8% | 40.1% | 20.6% |
| Net Income | $2,201 | $1,310 | $2,456 | $72 |
| % Margin | 18% | 10.7% | 21.9% | 0.6% |
| EPS Diluted | 1.08 | 0.64 | 1.2 | 0.035 |
| % Growth | 68.8% | -46.7% | 3,299.4% | – |
| Operating Cash Flow | $6,311 | $3,917 | $1,954 | $4,439 |
| Capital Expenditures | -$320 | -$361 | -$260 | -$378 |
| Free Cash Flow | $5,991 | $3,556 | $1,694 | $4,061 |